Actively Recruiting
Potential of Moderate Whole Body Hyperthermia to Enhance Response
Led by Charite University, Berlin, Germany · Updated on 2023-04-20
80
Participants Needed
1
Research Sites
252 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Using moderate whole-body hyperthermia (mWBH) in tumor patients to see the influence on circulating tumor cells, tumor response, quality of life, fatigue, psyche, immune response and tumor microenvironment
CONDITIONS
Official Title
Potential of Moderate Whole Body Hyperthermia to Enhance Response
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients must have a general health status suitable for multimodal treatment (WHO status 0-2)
- Diagnosis of one of the following cancers in a palliative setting: malignant melanoma stage IV without BRAF-V600 mutation planned for PD-1 and CTLA-4 antibody immunotherapy
- Metastatic or inoperable pancreatic cancer planned for first-line chemotherapy with FOLFIRINOX
- Hormone receptor-positive breast cancer planned for palliative radiation therapy with at least one additional untreated tumor lesion
- Metastatic high-grade sarcoma ineligible for ablative metastasis therapy planned for first-line doxorubicin therapy
- Metastatic or loco-regionally recurrent HPV-associated squamous cell carcinoma (head and neck, cervix, anus, vulva) planned for palliative first-line platinum therapy
- Metastatic castration-resistant prostate cancer with progressive disease after recommended therapies planned for lutetium-177-PSMA therapy
You will not qualify if you...
- Contraindications to simultaneous chemotherapy or whole-body hyperthermia
- Serious or active comorbidities that could interfere with treatment or study understanding, including:
- Chronic inflammatory bowel disease
- Acute infections
- Serious cardiovascular or pulmonary conditions
- Mental illnesses impairing study participation or understanding
- Presence of cerebral metastases
- Diabetes mellitus with risk of end-organ damage
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Klinik für Radioonkologie und Strahlentherapie
Berlin, Germany, 13353
Actively Recruiting
Research Team
S
Sebastian Zschaeck, MD
CONTACT
J
Julian Weingaertner, MD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here